Logo

Agilent's Projected Q3 Revenue Decline Improves Original Forecast

Jun 07, 2007
NEW YORK (GenomeWeb News) — Agilent Technologies today said it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, though it is a 1.5-percent improvement over earlier predictions.
 
During its fiscal second quarter earnings report in May, Agilent had said it expected third-quarter revenue to decline between 3.5 percent and 6.2 percent.  
 
Today, it said it expects revenue for the three months ended June 30 to decline to between $1.38 billion and $1.42 billion from $1.45 billion last year.
 

According to an Agilent spokesperson, last year’s results included revenue from Verigy, the semiconductor business the company spun off during the year. Adjusted for that discontinued operation for the third quarter of 2007, revenue was $1.2 billion, meaning that Agilent’s revised guidance represents a growth of between 11 percent and 15 percent.

 

 

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.